Empowering TIDES's commercial drug production with an integrated business system

CPHI CHINA 2026, "one of Asia's leading and highly authoritative industry exhibitions," concluded successfully in Shanghai. Over 3,600 industry-leading companies, bringing with them cutting-edge ideas and valuable resources for collaboration, returned to their respective business areas to deepen their industry practices. As a leading global one-stop integrated service platform for pharmaceutical outsourcing, Asymchem's core technical and business teams engaged in business discussions and exchanges with thousands of industry colleagues, experts, and partners over the three days. This has further boosted Asymchem's confidence as it embarks on a period of vigorous development in 2026.

At this exhibition, Asymchem's booth comprehensively showcased the company's "hexagonal" business capabilities, including small molecule chemicals, large molecule chemicals (peptides, oligonucleotides, etc.), ADC conjugates, formulations, synthetic biology services, and continuous reaction technology services. Under a highly integrated end-to-end model, multiple capabilities were effectively linked, and coupled with Asymchem's unique green chemistry solutions, it won unanimous recognition from industry experts and resulted in numerous potential cooperation intentions.

The company has firmly grasped the opportunities presented by the global market, maintaining its competitive advantage in the small molecule CDMO business globally, with services covering almost all small molecule drug synthesis and production. Its global footprint across China, the US, and the UK further meets diverse business needs, resulting in steady growth in operating performance.

The company has upgraded both its peptide and oligonucleotide (TIDES drugs) technology capabilities and production capacity. It has disrupted traditional production models to address the R&D and supply needs of next-generation TIDES drugs. From "single-point technological advantages" to "full-chain system capabilities," the company ensures the industrialization of related drug therapies from the perspectives of scale, speed, sustainability, supply security, and strategic layout.

The company's ADC and other conjugate CDMO business provides global clients with one-stop solutions for various novel conjugates, antibodies, and recombinant protein drugs. It has formed a commercial collaborative network with "R&D at the forefront, production at the center, and services globally," as well as a dual-site production layout in Jinshan and Fengxian, meeting the booming global market demand.

The company's formulation business capabilities continue to expand, with breakthroughs in new formulation types and significant commercialization achievements. Especially in new molecular type business areas such as TIDES, the company has covered technical pathways including salt form development, hot melt extrusion, spray drying, and nano-grinding, and has supporting oral formulation production capabilities, enabling the development of multiple dosage forms and GMP production.

Continuous reaction technology and equipment continue to be applied internally and exported externally, setting a benchmark for inherent safety, quality improvement, and efficiency enhancement in the industry. Projects for customers in the pharmaceutical, pesticide, and materials fine chemical fields have been successfully implemented, contributing to industrial upgrading.

Synthetic biology technology service capabilities have achieved further breakthroughs with the support of AI algorithms. A globally competitive underlying enzyme technology platform has achieved a fully automated process from enzyme design to product. The cell engineering platform has developed several advantageous products, including rhodioloside, resveratrol, perillaldehyde, and psoralen, and achieved efficient production.